This week in drug discovery (19-23 June)  

News round-up for 19-23 June by DDW Digital Content Editor Diana Spencer.

Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been the announcement of the FDA’s approval of the first gene therapy for Duchenne muscular dystrophy, and a caution from the Alliance for Regenerative Medicine (ARM) against the implementation of strict new clinical assessment rules in the EU.

The top stories:

Proposed EU clinical assessment rules would reject ATMPs

The proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorised in the EU, claims the Alliance for Regenerative Medicine (ARM).

Evox Therapeutics acquires exosome AAV technology from Codiak

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights.

FDA approves first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US.

A guide to using adeno-associated virus (AAV) vectors in gene therapy

This webinar will help you understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for enhanced therapeutic development.

Companies collaborate to improve cell therapy cryopreservation

Contract development and manufacturing organisation (CDMO) SCTbio and cell therapy company Cyto-care.eu have teamed up with the aim of improving the quality of cryopreservation in Europe.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free